Posts tagged TEVA


Dmitry Balyasny Gets Bullish on 3 Drug Makers: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Synergy Pharmaceuticals Inc (SGYP), Opko Health Inc. (OPK)

Risk-taker Dmitry Balyasny eyes advantage in the biotech world, between new initiations in TEVA, SGYP, and a major increase in OPK.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets a Price Target Reduction: Can It Hold Its Ground Short-Term?

Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.

Read more

Billionaire Israel Englander’s Surprising Q3 Moves In Biotech: Teva Pharmaceutical Industries Ltd (ADR) (TEVA), Valeant Pharmaceuticals Intl Inc (VRX), ACADIA Pharmaceuticals Inc. (ACAD)

Israel “Izzy” Englander isn’t afraid to go against the market on TEVA, VRX and ACAD.

Read more

Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) Headwinds Need to Be Tackled, But Potential Remains

Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.

Read more

This Analyst Is Struggling to See Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Find a Path for Growth

Unfavorable Teva risk/reward and steep valuation keeps Oppenheimer on the sidelines.

Read more

Analysts Weigh in on What Looming Debt Spells Out for Teva Pharmaceutical Industries Ltd (ADR) (TEVA) and Its Uncertain Future

From right and left, analysts to credit agencies are downgrading or cutting expectations on TEVA; here’s why.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets a Price Target Chop, But Not All Hope is Lost

Goldman Sachs: Cost cutting could be what TEVA needs to find stable ground once again.

Read more

Can Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Divest Its Way Out of Debt? This Analyst Doesn’t Believe So

Jason Kolbert: Rising generics rivalry coupled with price erosion do not bode positively for TEVA.

Read more

Louise Chen Raises Red Flags on Teva Pharmaceutical Industries Ltd (ADR) (TEVA); Here’s Why

Louise Chen is dialing down the price target on TEVA after a rocky third quarter performance.

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Completes Plan B One-Step Asset Sale To Foundation Consumer Healthcare For $675M

Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced it has completed the sale of Plan B …

Read more